Serial Screening and Treatment of Bacterial Vaginosis Trial
Launched by LOMA LINDA UNIVERSITY · Mar 11, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Serial Screening and Treatment of Bacterial Vaginosis Trial is studying whether having a bacterial infection called bacterial vaginosis (BV) can increase the chances of having a preterm delivery in women who have had a preterm birth before. This trial is looking for women who are pregnant and less than 32 weeks along, have had at least one previous preterm delivery, and are willing to follow the study’s treatment plan. To participate, women must be at least 18 years old and receive care at the Loma Linda Maternal Fetal Medicine Clinic.
If you join this study, you will be randomly placed in one of two groups: one group will be regularly tested for bacterial vaginosis and receive treatment if needed, while the other group will follow the standard care without the extra testing. The goal is to see if treating bacterial vaginosis can help reduce the risk of early delivery. It’s important to know that this trial does not include women who are not considered high risk for preterm delivery or those with certain medical conditions that could complicate their pregnancy.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female
- • Age greater than or equal to 18 years old
- • Pregnancy at less than 32 weeks gestational age at initial obstetric visit with Loma Linda Maternal Fetal Medicine (MFM) Clinic
- • History of at least one prior preterm delivery \>16 and \<37 weeks not due to iatrogenic indications, or short cervical length \<2.5cm
- • Willing to receive prenatal standard of care and comply with treatment plan and other study procedures at Loma Linda
- Exclusion Criteria:
- • Patients not deemed to be high risk for preterm delivery
- • Patient with cervical dilation ≥1cm on initial exam or with protruding membranes
- • Current pregnancy is multigestation
- • Medical indications for iatrogenic preterm delivery during this pregnancy (e.g. preeclampsia with severe features)
- • Desires termination during this pregnancy
About Loma Linda University
Loma Linda University is a prominent academic institution dedicated to advancing health and wellness through innovative research and education. As a sponsor of clinical trials, Loma Linda University leverages its extensive medical and scientific expertise to conduct rigorous studies aimed at improving patient outcomes and public health. With a commitment to ethical practices and patient safety, the university collaborates with a diverse network of healthcare professionals and researchers to explore novel therapeutic interventions and enhance clinical knowledge across various medical disciplines. Through its clinical trials, Loma Linda University seeks to contribute valuable insights to the medical community and foster advancements in healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Loma Linda, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials